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Summary
Objective: To measure the impact of invasive aspergillosis infection on US hospital costs and
financial performance across different patient populations.
Methods: Hospital dischargedata for patientswith a primary or secondary diagnosis of aspergillosis
were extracted from the 2003 Nationwide Inpatient Sample (NIS) and the fiscal year 2003 (FYO3)
Medicare Provider Analysis and Review (MedPAR) file. The data on patient demographics, length of
stay (LOS), hospital charges, estimated costs, and reimbursement levels were reported. After
controlling for comorbidities, operativeprocedures, anddiagnosis-relatedgroup (DRG) assignment,
the clinical and economic outcomes were compared for patients with and without aspergillosis.
Results: The NIS contains a total of over 38 million projected hospital discharges. From these,
10 400 aspergillosis cases were identified across 171 DRGs, resulting in a US incidence rate of 36 per
million per year. The mean age of aspergillosis patients was 55.6 years, with 53.4% male and 67.9%
Caucasian. The median (mean) LOS per aspergillosis patient was 10 (17.7) days, with a median
(mean) total hospital charge (THC) of $44 845 ($96 731). Among the patient subgroups analyzed,
the median (mean) THC per patient ranged from $47 252 ($82 946) for HIV to $413 200 ($442 233)
for bonemarrow transplant (BMT).When compared to the non-aspergillosis patient population, the
data showed a significant increase in LOS, THC, and hospital costs. Furthermore, the higher
hospital costs associated with aspergillosis patients were not matched by similar increases in
reimbursements, resulting in a greater financial loss for hospitals. The mean reimbursement-to-
cost ratio for aspergillosis cases across the DRGs analyzed was 0.80.
Conclusions: Aspergillosis affects a wide range of patient groups and has a negative economic
impact across many DRGs. Improved prevention, diagnosis, and patient management strategies
can help mitigate these effects on hospital financial performance.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +1 415 835 0190; fax: +1 415 835 0199.
E-mail address: info@quorumconsulting.com (K.B. Tong).
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Aspergillosis is associated with high morbidity and mortality,
particularly in immunocompromised patients with risk fac-
tors such as bone marrow transplantation (BMT), solid organ
transplantation, neutropenia, hematologic malignancy, HIV,
immune dysfunction, chemotherapy, or corticosteroid ther-
apy.1,2 Studies have reported a mortality rate of over 80% in
BMT recipients with invasive aspergillosis, 90% in liver trans-
plant recipients, and 49% in patients with leukemia or lym-
phoma.3,4 In an interim analysis conducted by the Transplant
Associated Infections Surveillance Network (TransNet), the
researchers reported hematopoietic stem cell and solid organ
transplant estimated case incidence rates ranging from 0.5%
to 3.9% among different types of stem cell transplants, and
0.1% to 2.4% among different solid organ transplants.5
Research also suggests that the incidence of aspergillosis
is increasing. Groll et al. documented a rise in the rate of
invasive mycoses from 1% to 7% of all autopsies performed
between 1978 and 1992, and a proportional increase of
invasive aspergillosis from 17% to 60% of all mycoses found
on autopsy.6 Another study estimated that in 1996, rates of
aspergillosis infections had risen to 38 per million hospital
discharges.7 This trend may be attributed in part to the
growing incidence of HIV infection, intensity of chemother-
apy regimens, and increased number of bone marrow and
solid organ transplants.8,9 At one major bone marrow trans-
plant center, the risk of invasive aspergillosis grew from 4% to
12%.10 Treatment guidelines have addressed the growing
concern for aspergillosis infection in immunocompromised
hosts. In BMT, for example, attention has shifted from tradi-
tional anti-yeast prophylaxis to include anti-mold prophylaxis
in high-risk patients.11,12
As part of a study on the direct costs of systemic fungal
infection, Wilson et al. demonstrated that costs associated
with aspergillosis are high, with total inpatient and out-
patient costs of $674.1 million and an overall incremental
hospitalization cost of $36 867 per incident.13 However,
the need remains for an in-depth evaluation of the impact
of aspergillosis on healthcare and economic outcomes.
While previous studies have estimated the total costs of
aspergillosis, few attempts have been made to character-
ize the clinically relevant subgroups of patients affected.
Because of the focus on overall costs alone, the economic
impact of aspergillosis in certain patients may be
underestimated. Identifying clinically relevant subgroups
is a requisite step in being able to quantify the full cost
of aspergillosis and to develop targeted therapeutic inter-
ventions for both the prevention and treatment of this
disease.
This study examines the economic impact of aspergillosis
in a variety of clinically relevant patient subgroups from the
hospital inpatient perspective. To understand the impact of
aspergillosis on hospital expenditures, interactions between
aspergillosis and the diagnosis-related group (DRG) system
are described. DRGs provide the basis for the hospital inpa-
tient prospective payment system (PPS) to reimburse hos-
pitals for care of Medicare, Medicaid, and an increasing
number of commercially insured patients. Utilizing DRGs
as the denominator for analysis provides a natural frame-
work to understand the burden of disease from the hospital
point of view.Methods
Databases
Two databases were utilized as data sources for analysis. The
2003 Nationwide Inpatient Sample (NIS) was developed as
part of the Healthcare Cost and Utilization Project, and is the
largest all-payer inpatient care database publicly available in
the US.14 The 2003 NIS consists of approximately 7.5 million
hospital stays from 994 hospitals in 28 states, representing a
stratified sample of 20% of all US community hospitals. Each
record in the NIS contains information about a patient’s
hospital stay, documenting demographics, specific diagnoses
and procedures, patient disposition, payer type, and overall
hospital charges. All analyses were performed on the NIS,
with the exception of those involving specific hospital
charges and amounts reimbursed.
Because the NIS is a sample of hospital discharges, it is
possible to create national estimates based on the data using
discharge weights that are defined for every discharge
record. This was particularly useful for the purposes of
generating a socio-demographic profile of aspergillosis with
incidence rates at the national level (see below, Incidence
and disease profile).
The Medicare Provider Analysis and Review (MedPAR) file
for fiscal year 2003, acquired from the Centers for Medicare
and Medicaid Services (CMS), contains detailed charge infor-
mation for 100% of Medicare beneficiaries using hospital
inpatient services (approximately 11.5 million records).15
Particularly useful to this study were data elements in each
record that were not captured by the NIS, including specific
categories of hospital charges as well as reimbursement
amounts. While the patient populations represented by
the NIS and MedPAR data were distinct, preliminary analysis
of median and mean total hospital charges (THC) within
various DRGs generally showed agreement between the
two databases. Therefore, the MedPAR file was primarily
used to examine specific hospital charges and reimbursed
amounts.
Definition of aspergillosis patient population
For all analyses, patients were considered to have aspergil-
losis if they had a primary or secondary discharge diagnosis of
aspergillosis, using the International Classification of Dis-
eases, Ninth Revision, Clinical Modifications (ICD-9-CM) code
117.3. Discharge diagnoses are reported on hospital claim
forms according to the healthcare provider’s clinical assess-
ment of the patient’s condition.
Incidence and disease profile
A socio-demographic profile of aspergillosis patients as a
whole was generated by examining patient age, race, gender,
and payer mix. In addition, outcome-related variables
including length of stay (LOS) and THC were analyzed. NIS
weighted estimates were used to calculate US national
aspergillosis incidence projections, assuming a 2003 US popu-
lation of 290 788 976.16
While limitations of the data available precluded the
possibility of performing a full analysis based on the location
Table 1 The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups from the 2003
Nationwide Inpatient Sample
Characteristic Aspergillosis patients Non-aspergillosis patients
Mean or n SD or % Mean or n SD or %
Number of cases, unweighted 2143 7 975 585
Number of cases, weighted 10 400 38 210 191
Aspergillosis diagnosis
Primary 3060 29.4%
Secondary 7340 70.6%
Mortality rate 1778 17.1% 847 489 2.2%
Mean age 55.6 years  19.0 years 48.2 years  21.8 years
Age distribution
<18 years 493 4.7% 60 635 11.7%
18—44 years 2109 20.3% 147 823 28.6%
45—64 years 3929 37.8% 177 625 34.4%
65+ years 3869 37.2% 130 016 25.2%
Gender
Male 5557 53.4% 290 113 56.3%
Female 4843 46.6% 225 340 43.7%
Race
White 5418 67.9% 240 436 58.1%
Black 1359 17.0% 88 054 21.3%
Hispanic 741 9.3% 60 154 14.5%
Other 456 5.7% 25 365 6.1%
Payer
Medicare 4656 44.8% 181 691 35.2%
Medicaid 1468 14.1% 100 882 19.6%
Private insurance 3734 35.9% 192 693 37.4%
Self-pay 220 2.1% 18 493 3.6%
Other 311 3.0% 21 898 4.2%
Mean length of stay 17.7 days  21.9 days 7.9 days  11.4 days
Mean total hospital charges $96 731  $134 073  $44 318  $78 670
SD, standard deviation. Note: Values are weighted to project national estimates. Missing values resulted in sample variations across certain
variables; percentages were calculated after omitting missing values.
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aspergillosis patient population based on the presence or
absence of a secondary ICD-9-CM code for pneumonia in
aspergillosis (484.6) was possible. Because pulmonary asper-
gillosis represents a serious, systemic infection, it was
expected that on average, aspergillosis patients classified
with Aspergillus pneumonia would have poorer outcomes
(defined by LOS, THC, and inpatient mortality) than those
who did not.
Patient subgroup analysis
There has been some debate about the makeup of the
aspergillosis population. In a study involving a series of 595
invasive aspergillosis patients, Patterson et al. retrospec-
tively reported that almost 80% had BMT, hematologic dis-
ease, solid organ transplant, or AIDS.17 However, a separate
study that reviewed hospital discharge data from 1998 found
that the most commonly cited comorbidities for fungal infec-
tions — HIV, neoplasms, and transplants — accounted for only
45% of all infections.13 In light of this, the DRG analysis wasapproached in two ways: (1) through the characterization of
high-risk DRGs previously described in the literature, and (2)
through the characterization of the DRGs most commonly
assigned to aspergillosis patients, identified on the basis of
frequency.
In the first method, clinically relevant conditions known to
place patients at high risk for invasive aspergillosis were
identified from the literature. DRGs corresponding to these
risk factors included BMT (DRG 481), hematologic malignancy
(DRG 400—405 and 473), immunity disorders (DRG 398—399),
HIV infection (DRG 488—490), solid organ transplantation
(DRG 103, 302, 480, 495), and chemotherapy (DRG 410 and
492). In addition, the same literature found that patients who
have undergone transplantation remain at elevated risk for
aspergillosis during the weeks and months following the
transplant procedure.18—21 Therefore, it was of interest to
analyze data from the population of post-transplant patients
who contracted aspergillosis after their initial hospitaliza-
tion. This cohort cannot be captured using the DRG system
because there are no post-transplant DRGs. To overcome this
limitation, ICD-9-CM codes corresponding to complications of
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lung (996.84), and bone marrow (996.85) were used to define
the post-transplant patient population. To eliminate any
overlap with patients hospitalized for a transplantation pro-
cedure, we excluded admissions that were concurrently
assigned a transplant DRG.
In the second method, all the DRGs found within the
aspergillosis patient population were tabulated, and the
most commonly assigned DRGs were identified based on
frequency. This approach served two purposes. First, by
identifying the number of DRGs associated with aspergillosis,
it provided a context for the data obtained from each sub-
group. Secondly, it provided a third subgroup solely based on
raw data.
Subgroups of aspergillosis patients assigned to each of
the DRG or ICD-9-CM categories above were analyzed and
descriptive statistics generated for LOS and overall charges
based on NIS data. For DRG defined subgroups, MedPAR
data for specific and total hospital charges and costs as
well as total amounts reimbursed were analyzed. Because
the focus of this study was to describe costs from the
hospital inpatient perspective, analysis was not performed
for post-transplant ICD-9-CM categories, since each ICD-9-
CM code would have represented a heterogeneous collec-
tion of DRGs. Each subgroup was compared to a reference
population consisting of all patients within the same DRG
or ICD-9-CM category who did not carry a diagnosis of
aspergillosis.
CMS’s 2004 Quarter 4 (Q4) hospital cost report data files
were used to calculate provider-specific cost-to-charge
ratios (RCC). For each discharge in MedPAR, the total
charges were multiplied by the provider specific RCC to
calculate an estimated cost. Incremental costs were deter-
mined by subtracting the median hospital costs of the
non-aspergillosis reference population from the median
hospital costs of patients with aspergillosis. Specific
charges, particularly the expense categories of pharmacy,
accommodation, intensive care unit (ICU), laboratory, and
medical supplies were examined separately. All other spe-
cific charge categories were grouped as ‘other’. When
analyzing reimbursement amounts, a reimbursement-to-
cost ratio (RCR) was calculated by dividing the median
total amount reimbursed by the median hospital cost for
each DRG examined. An incremental reimbursement-to-
cost ratio (IRCR) was also defined for each DRG to deter-
mine to what extent incremental costs attributable to
Aspergillus infection were reimbursed. The IRCR wasTable 2 Length of stay, total hospital charges, andmortality in asp
the 2003 Nationwide Inpatient Sample
Aspergillosis patients (N = 10 400) With Aspergillus pneum
Number of cases (%) 3910 (37.6%)
Median LOS, days (min—max) 13.0 (0.0—204.0)
Mean LOS, days (SD) 20.8 (22.5)
Median THC, $ (min—max) 66 122 (658—941 043)
Mean THC, $ (SD) 120 910 (147 990)
% Hospital mortality 25.1%
LOS, length of stay; SD, standard deviation; THC, total hospital char
variations across variables; percentages were calculated after omittincalculated by computing the difference between median
reimbursed amounts for patients with and without asper-
gillosis and dividing this result by the difference between
median hospital costs for patients with and without asper-
gillosis.
Chi-square tests were performed to describe statistically
significant differences between categorical variables, except
when small sample sizes made the Fisher’s exact test more
appropriate. Student’s t-tests were performed to identify
significant differences between means. The level of signifi-
cance was set at 0.01. All analyses were performed using
SPSS v12.
Results
Incidence of aspergillosis
Out of 38 million (weighted) hospital discharges in the 2003
NIS, 10 400 aspergillosis cases were identified across 171
DRGs. Aspergillosis was reported as the primary diagnosis
for 29.4% of these cases. Assuming a 2003 US population of
290 million, we calculated a national incidence of 36 per
million per year. Table 1 summarizes demographic character-
istics as well as LOS andmean THC for aspergillosis patients as
a whole. The mortality rate was 17.1%. The mean age of
aspergillosis patients was 55.6 years. Approximately half
(53.4%) weremale and almost two-thirds (67.9%) were white.
Medicare and private insurance were the largest payers of
hospitalization expenses, each covering roughly 45% and 36%,
respectively.
Aspergillosis patients with and without
pneumonia
Of the 10 400 aspergillosis cases found in the NIS, 3910
(37.6%) were diagnosed with pneumonia in aspergillosis.
Table 2 summarizes the median and mean LOS and THC,
as well as hospital mortality rates for aspergillosis
patients with and without the additional diagnosis of
pneumonia in aspergillosis. The mean LOS, THC, and mor-
tality were all significantly higher in those patients who
had Aspergillus pneumonia compared with those patients
who did not have Aspergillus pneumonia ( p < 0.01). A
complete list of the top ten commonly co-reported diag-
nosis codes for aspergillosis hospital discharges can be
found in Appendix A.ergillosis patients with and without Aspergillus pneumonia from
onia Without Aspergillus pneumonia p-Value
6486 (62.4%)
9.0 (0.0—235.0)
15.8 (21.2) <0.01
36 264.00 (51—864 986)
82 406 (122 888) <0.01
12.4% <0.01
ge. Note: Data from 2003 NIS. Missing values resulted in sample
g missing values.
Table 3 Contribution of various DRG and ICD-9-CM categories to total cases of aspergillosis for high-risk DRG categories and post-
transplant ICD-9-CM categories in the 2003 Nationwide Inpatient Sample
Number of cases Rate of Asp cases
in subgroup (%)
% of total Asp
cases (N = 10 400)
Asp Non-Asp
High-risk DRG categories
Hematologic malignancy 503 124 924 0.40 4.8
HIV 380 87 854 0.43 3.7
Chemotherapy 283 140 315 0.20 2.7
BMT 114 10 517 1.1 1.1
Reticuloendothelial/immunity disorders 110 72 911 0.15 1.1
Total 1390 436 521 0.32 13.4
Post-transplant ICD-9-CM categories
Complications of BMT 229 6584 3.4 2.2
Complications of lung transplant 285 5702 4.8 2.7
Complications of kidney transplant 63 36 561 0.17 0.61
Complications of heart transplant 29 5148 0.56 0.28
Complications of liver transplant 25 8597 0.29 0.24
Total 631 62 592 1.0 6.1
Asp, aspergillosis; DRG, diagnosis-related group; HIV, human immunodeficiency virus; BMT, bone marrow transplant.
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DRG categories and post-transplant patients
Analysis was performed on 1390 patients in the following
high-risk DRG categories: hematologic malignancy, HIV,
chemotherapy, BMT, and reticuloendothelial and immunity
disorders. The DRGs for solid organ transplantation were
not analyzed due to low numbers (total n = 68). We also
analyzed the following post-transplant patients (n = 631)
grouped by ICD-9-CM code: bone marrow, lung, kidney,
heart, and liver. Altogether, these high-risk patients com-
prised 19.4% of the aspergillosis population (Table 3).
Approximately 1.1% of BMT hospitalizations were asso-
ciated with a diagnosis of aspergillosis, 2.5 to 7 times
higher than in other high-risk DRG categories. Within the
identified post-transplant patient population, cases of
aspergillosis were proportionally highest in hospitalizations
related to complications of lung transplant (4.8%) and
complications of BMT (3.4%).
Table 4 compares median and mean LOS and THC for these
patient subgroups with and without aspergillosis. Compared
to non-aspergillosis patients within the same DRG or ICD-9-
CM category, median LOS was 1.8 to 12.4 times higher and the
median THC per admission in aspergillosis patients was 2.3 to
12.7 times higher. These differences were significant in all
patient subgroups except for post-heart and post-liver trans-
plant patients, where small sample sizes were a concern.
Among all patients, the mean THC of those with aspergillosis
ranked above the 90th percentile for all high-risk DRG cate-
gories examined.
Among the high-risk DRG subgroup, Aspergillus-
infected BMT patients stayed in the hospital the longest
(median LOS 48 days), and had the most expensive
hospitalizations (median THC = $413 200). Within the
post-transplant patient category, liver transplant patients
with aspergillosis had the longest and most expen-sive hospitalizations (median LOS = 62 days; median
THC = $291 158).
Length of stay and hospital charges for the top
five most common DRGs
In determining the most commonly assigned DRGs among
the aspergillosis patients, 171 different DRG classifications
were found to be associated with an aspergillosis diagnosis.
The five most commonly assigned DRGs among the asper-
gillosis patients in order of frequency were: infectious and
parasitic diseases (DRG 423, n = 2014), operating room (OR)
procedures for infectious and parasitic diseases (DRG 415,
n = 1087), tracheostomy (DRG 483, n = 567), respiratory
system diagnoses with ventilator support (DRG 475,
n = 471), and chronic obstructive pulmonary disease (COPD;
DRG 79, n = 452). Combined, these patients comprised
44.1% of the aspergillosis population (Table 5). Aspergillosis
patients with tracheostomy (DRG 483) had the longest
hospital stay (median LOS = 49.5) and the highest THC
(median THC = $309,351) of all DRG categories examined
(Table 6).
Specific hospital charges and costs
Specific hospital charges and costs were also analyzed across
high-risk DRGs and the five most commonly assigned DRGs.
Pharmacy and accommodation charges represented the high-
est proportion (50—70%) of hospital charges in all DRGs
examined. In general, specific charges within high-risk DRGs
increased four to six times in aspergillosis patients; ICU
charges increased tenfold.
With respect to the total hospital cost for aspergillosis
patients, pharmacy, ICU, and laboratory expenditures were
the most significant contributors across the DRGs analyzed.
On average, pharmacy costs represented 30% of total
Table 4 Length of stay and total hospital charges by associated DRG or ICD-9-CM category, aspergillosis vs. non-aspergillosis patients for high-risk DRG categories and post-transplant
ICD-9-CM categories in the 2003 Nationwide Inpatient Sample
Length of stay Total hospital charges
Median, days (min—max) Mean, days (SD) p-Value Median, $ (min—max) Mean, $ (SD) p-Value
Asp Non-Asp Asp Non-Asp Asp Non-Asp Asp Non-Asp
High-risk DRG categories
Hematologic
malignancy
30.0 (1.0—172.0) 6.0 (0.0—351.0) 34.8 (31.7) 9.3 (11.4) <0.01 149 912 (7519—747 897) 22 157 (73—957 245) 191 974 (163 535) 45 064 (69 220) <0.01
HIV 11.0 (1.0—73.0) 6.0 (0.0—302.0) 14.2 (12.8) 8.6 (9.9) <0.01 47 252 (2826—316 110) 20 115 (72—974 336) 82 946 (78 884) 38 173 (57 641) <0.01
Chemotherapy 8.0 (0.0—92.0) 4.0 (0.0—153.0) 19.9 (20.5) 4.8 (6.1) <0.01 50 196 (1979—525 848) 16 005 (158—942 096) 87 624 (97 349) 26 045 (38 298) <0.01
BMT 48.0 (20.0—130.0) 23.0 (1.0—254.0) 56.9 (26.2) 28.1 (19.1) <0.01 413 200 (60 386—808 002) 151 791 (5091—995 571) 442 233 (236 014) 203 603 (165 034) <0.01
Reticuloendothelial/
immunity disorders
9.0 (3.0—107.0) 4.0 (0.0—346.0) 18.9 (23.3) 5.0 (6.2) <0.01 49 703 (9321—794 716) 11 574 (30—978 516) 112 892 (169 865) 20 811 (41 576) <0.01
Post-transplant ICD-9 categories
Complications of BMT 15.0 (2.0—107.0) 6.0 (0.0—145.0) 23.6 (22.1) 11.5 (15.9) <0.01 93 857 (5100—794 716) 33 027 (1926—978 516) 180 843 (189 619) 80 513 (134 615) <0.01
Complications
of lung transplant
11.0 (2.0—190.0) 6.0 (0.0—260.0) 24.0 (38.8) 11.3 (16.6) <0.01 90 622 (6144—534 184) 36 267 (2323—961 072) 153 796 (146 252) 81 558 (130 736) <0.01
Complications
of kidney transplant
14.0 (4.0—61.0) 5.0 (0.0—196.0) 25.8 (21.3) 7.5 (10.4) <0.01 206 289 (15 957—511 774) 19 053 (548—957 763) 191 986 (136 382) 39 732 (70 425) <0.01
Complications
of heart transplant
14.6 (3.0—36.0) 5.0 (0.0—230.0) 15.1 (11.3) 8.3 (14.6) <0.01 88 557 (48 800—768 054) 33 970 (1787—897 011) 210 128 (274 304) 68 808 (106 533) <0.01
Complications
of liver transplant
62.0 (4.0—138.0) 5.0 (0.0—241.0) 53.2 (50.9) 10.3 (17.5) <0.01 291 158 (19 574—562 742) 22 821 (1023—917 140) 291 158 (286 294) 54 475 (95 895) 0.03
DRG, diagnosis-related group; SD, standard deviation; Asp, aspergillosis; BMT, bone marrow transplant. Note: Missing values resulted in sample variations across variables; percentages were calculated after
omitting missing values.
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Table 5 Contribution of various DRG and ICD-9-CM categories to total cases of aspergillosis for the top five most common DRGs in
the 2003 Nationwide Inpatient Sample
Number of cases Rate of Asp cases
in subgroup (%)
% of total Asp
cases (N = 10 400)
Asp Non-Asp
Top five most common DRGs
Infectious and parasitic diseases 2014 22 552 8.2 19.4
OR procedures for infectious
and parasitic diseases
1087 101 904 1.1 10.5
Tracheostomy 567 99 565 0.57 5.5
Respiratory system diagnoses
with ventilator support
471 217 439 0.22 4.5
COPD 452 684 860 0.07 4.3
Total 4591 1 126 320 0.41 44.1
DRG, diagnosis-related group; Asp, aspergillosis; OR, operating room; COPD, chronic obstructive pulmonary disease.
30 K.B. Tong et al.expenditures, while ICU and laboratory costs represented
roughly 12.2% and 11.8%, respectively.
Estimated total hospital cost and incremental
hospital cost by DRG
Table 7 presents estimated total hospital costs by DRG in
aspergillosis and non-aspergillosis patients and the incremen-
tal costs associated with aspergillosis. Within the high-risk
DRG category, BMT patients with aspergillosis incurred the
highest median estimated costs, $74 945, over two times the
amount for non-aspergillosis patients ($33 055). However, in
terms of incremental costs, both hematologic malignancy
and chemotherapy patients experienced large relative
increases in expenditures, over 600% and 800%, respectively.
Although patients within the reticuloendothelial/immunity
disorder DRG displayed the lowest median costs, the asper-
gillosis cases resulted in a 162% increase in hospital cost.
When examining cost by the five most common DRGs,
tracheostomy procedures produced the highest median esti-
mated costs in both aspergillosis and non-aspergillosis
patient groups ($87 729 and $64 938, respectively). Infec-
tious and parasitic diseases experienced the largest relative
increase in cost (98.30%). Estimated costs associated with
COPD were the lowest across the five most common DRGs,
resulting in a median estimated cost of $5924 for aspergillosis
patients and $3417 for non-aspergillosis patients. Hospitals
managing patients within this subgroup experienced a 73.37%
increase in costs.
Reimbursed amounts by DRG
Median and mean THC and reimbursed amounts for Medicare
patients with aspergillosis are listed in Table 8. As would be
expected, both median and mean reimbursed amounts were
higher in cases involving aspergillosis than in those not
involving aspergillosis. However, as shown in Table 9, cases
involving aspergillosis were on average reimbursed a lower
percentage of their total cost than non-aspergillosis cases
(mean RCR, 0.80 vs. 1.43, respectively). Additionally, incre-
mental costs associated with aspergillosis were reimbursed
at a very low rate with a mean IRCR of 0.30. The IRCR forindividual DRG categories ranged from 0.08 (infectious and
parasitic diseases) to 0.52 (chemotherapy and HIV). For
aspergillosis patients, the RCRs were lower than the corre-
sponding ratios for non-aspergillosis cases in all DRG cate-
gories.
Discussion
Aspergillosis is found in approximately 0.03% of all hospitali-
zations. The estimated US incidence rate of 36 permillion per
year confirms previous estimates of the incidence of asper-
gillosis.13 While the number of incident cases is fairly small,
aspergillosis has a significant impact on: (1) patients —
aspergillosis affects a diverse patient population, with the
10 400 cases in our dataset spread across 171 DRGs, and (2)
hospitals — expenses associated with Aspergillus infection
were disproportionately large.
Impact of aspergillosis
Diverse patient population
Clinical attention has naturally focused on well-known risk
factors for invasive aspergillosis in immunosuppressed
patients. The rates of aspergillosis we found among hospi-
talizations for BMT (1.1% and 3.4% for preoperative period
and post-transplant, respectively), complications of lung
transplant (4.8%), HIV (0.4%), and hematologic malignancy
(0.4%) are consistent with what has previously been
reported.8 However, patients assigned to high-risk DRGs
and post-transplant ICD-9-CM categories comprised only
19.4% of aspergillosis hospitalizations. On the other hand,
the top five most common DRGs comprised 44.1%, with none
of the top five belonging to a readily identifiable high-risk
category. Moreover, the finding that an additional 161 DRG
classifications were associated with incidents of aspergillosis
only further demonstrates the diversity of the population
that aspergillosis has an impact on.
The top two most common DRGs found in our analysis:
infectious and parasitic disease diagnoses (423, 415), appear
largely to represent a general, chronically ill population
without classic risk factors for invasive disease. The DRG
for COPD (79) includes patients who had comorbid conditions
Table 6 Length of stay and total hospital charges by associated DRG or ICD-9-CM category, aspergillosis vs. non-aspergillosis patients for the top five most common DRGs in the 2003
Nationwide Inpatient Sample
Length of stay Total hospital charges
Median, days, (min—max) Mean, days (SD) p-Value Median, $ (min—max) Mean, $ (SD) p-Value
Asp Non-Asp Asp Non-Asp Asp Non-Asp Asp Non-Asp
Top five most common DRGs
Infectious and
parasitic
diseases
8.0 (0.0—87.0) 4.0 (0.0—145.0) 10.4 (10.4) 6.8 (8.1) <0.01 29 878 (658—766 488) 12 962 (35—854 046) 52 024 (78 471) 27 271 (45 161) <0.01
OR procedures
for infectious
and parasitic
diseases
13.0 (0.0—165.0) 9.0 (0.0—259.0) 16.9 (15.7) 12.7 (13.1) <0.01 66 043 (6241—426 406) 32 882 (32—999 346) 94 569 (86 778) 58 692 (79 640) <0.01
Tracheostomy 49.5 (1.0—63.0) 32.0 (0.0—265.0) 55.7 (38.0) 40.0 (32.2) <0.01 309 351 (1765—185 101) 208 664 (48—933 005) 358 931 (226 806) 261 087 (194 973) <0.01
Respiratory
system
diagnosis with
ventilator
support
15.0 (8.0—235.0) 8.0 (0.0—362.0) 20.2 (15.8) 11.0 (11.5) <0.01 103 007 (56 205—941 043) 42 979 (35—999 945) 136 153 (105 923) 64 334 (72 905) <0.01
COPD 7.0 (0.0—50.0) 4.0 (0.0—261.0) 11.0 (11.4) 4.6 (3.9) <0.01 18 307 (2497—513 178) 9847 (94—916 925) 30 933 (37 084) 14 217 (15 965) <0.01
DRG, diagnosis-related group; SD, standard deviation; Asp, aspergillosis; OR, operating room; COPD, chronic obstructive pulmonary disease. Note: Missing values resulted in sample variations
across variables; percentages were calculated after omitting missing values.
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Table 7 Total hospital costs by associated DRG, aspergillosis vs. non-aspergillosis patients in the 2003 MedPAR
Median costs, $ (min—max) Mean costs, $ (SD) Incremental median cost
Asp Non-Asp Asp Non-Asp $ Difference % Increase
High-risk DRG categories
Hematologic malignancy 47 949 (0—247 250) 6570 (0—962 484) 55 292.33 (47 425.67) 11 575.73 (16 883.29) 41 379.40 629.85%
HIV 15 944 (0—84 448) 5905 (0—465 763) 23 374.35 (20 885.76) 10 107.73 (14 794.25) 10 039.70 170.03%
Chemotherapy 45 214 (1297—175 800) 4917 (0—249 391) 48 830.36 (36 115.95) 7746.36 (11 457.99) 40 297.45 819.58%
BMT 74 945 (23 956—272 912) 33 056 (0—389 799) 109 013.59 (82 246.43) 43 306.94 (42 218.08) 41 889.07 126.72%
Reticuloendothelial/
immunity disorders
11 270 (0—278 987) 4301 (0—288 617) 40 289.82 (67 231.63) 6287.02 (8437.65) 6968.42 162.01%
Top five most common DRGs
Infectious and
parasitic diseases
9856 (0—163 019) 4970 (0—158 251) 15 042.64 (18 375.63) 8901.55 (12 327.88) 4886.06 98.30%
OR procedures for
infectious and
parasitic diseases
19 556 (0—176 771) 12 036 (0—2 129 893) 28 718.60 (26 856.63) 18 709.17 (23 719.57) 7520.49 62.48%
Tracheostomy 87 729 (0—430 429) 64 938 (0—1 593 666) 101 522.94 (69 196.48) 81 134.54 (66 399.87) 22 790.80 35.10%
Respiratory system
diagnosis with
ventilator support
26 252 (0—261 599) 13 474 (0—1 010 665) 33 787.87 (31 680.46) 18 548.40 (19 683.88) 12 777.20 94.83%
COPD 5924 (0—82 289) 3417 (0—288 989) 9485.55 (10 956.42) 4471.06 (4261.07) 2507 73.37%
DRG, diagnosis-related group; MedPAR, Medicare Provider Analysis and Review file; SD, standard deviation; Asp, aspergillosis; BMT, bone marrow transplant; OR, operating room; COPD, chronic
obstructive pulmonary disease.
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Table 8 Total hospital charges and reimbursed amounts by associated DRG category, aspergillosis vs. non-aspergillosis from the 2003 MedPAR
Number of
cases
Total hospital charges Reimbursed amounts
Median, $ (min—max) Mean, $ (SD) Median, $ (min—max) Mean, $ (SD)
Asp Non-Asp Asp Non-Asp Asp Non-Asp Asp Non-Asp Asp Non-Asp p-Value
High-risk DRG categories
Hematologic
malignancy
117 60 517 123 139 (4678—1 736 649) 19 556 (5—2 276 578) 183 166 (232 394) 36 522 (56 293) 23 371 (0—517 679) 9568 (0—830 478) 44 371 (62 841) 12 316 (12 594) <0.01
HIV 81 20 214 46 499 (5920—400 156) 17 690 (114—1 644 000) 77 924 (74 262) 33 289 (54 133) 14 512 (0—55 480) 9328 (0—505 669) 17 992 (13 102) 11 366 (11 529) <0.01
Chemotherapy 64 33 435 111 335 (3248—544 893) 14 817 (293—890 563) 150 513 (126 946) 24 484 (37 184) 26 703 (0—138 785) 5647 (0—242 910) 35 121 (26 847) 8131 (9404) <0.01
BMT 24 20 328 245 598 (53 867—878 671) 97 948 (3063—830 109) 101 820 (129 528) 19 567 (29 755) 60 929 (42 214—261 860) 47 057 (0—318 297) 26 348 (39 328) 6288 (6749) 0.02
Reticuloendothelial/
immunity disorders
19 993 40 494 (2564—469 379) 12 433 (15—1 779 806) 306 449 (244 879) 128 792 (105 638) 7103 (0—162 817) 5763 (0—558 998) 97 022 (68 825) 50 478 (29 622) 0.03
Top five most common DRGs
Infectious and
parasitic diseases
843 8179 28 193 (1452—600 417) 14 673 (17—981 571) 46 644 (57 134) 28 097 (41 321) 8813 (0—200 004) 8420 (0—196 958) 11 567 (12 952) 9774 (7955) <0.01
OR procedures for
infectious and
parasitic diseases
398 46 811 63 114 (3827—1 012 735) 35 911 (67—7 453 037) 91 291 (98 185) 61 117 (90 854) 20 549 (0—237 714) 18 320 (0—2 961 377) 25 599 (19 649) 21 617 (21 505) <0.01
Tracheostomy 175 45 745 262 790 (17 172—1 987 949) 195 583 (40—5 881 797) 333 252 (297 415) 260 736 (249 904) 97 807 (0—459 114) 88 230 (0—1 503 270) 110 004 (65 152) 99 461 (62 565) 0.03
Respiratory system
diagnosis with
ventilator support
248 120 419 82 628 (5852—1 061 907) 42 395 (8—2 790 084) 119 824 (116 700) 64 195 (75 677) 20 620 (0—236 424) 18 175 (0—735 914) 27 534 (23 723) 21 287 (14 326) <0.01
COPD 317 418 414 19 440 (1765—514 010) 9773 (9—1 075 344) 32 475 (46 186) 14 388 (16 646) 4016 (0—115 118) 3780 (0—213 937) 6486 (9802) 4199 (2846) <0.01
DRG, diagnosis-related group; MedPAR, Medicare Provider Analysis and Review file; SD, standard deviation; Asp, aspergillosis; BMT, bone marrow transplant; OR, operating room; COPD, chronic obstructive pulmonary disease.
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Table 9 Reimbursement-to-cost ratio (RCR) and incremental reimbursement-to-cost ratio (IRCR) by DRG category, aspergillosis
vs. non-aspergillosis hospitalizations from the 2003 MedPAR
DRG category RCR IRCR
Asp Non-Asp
Hematologic malignancy 0.49 1.46 0.33
HIV 0.91 1.58 0.52
Chemotherapy 0.59 1.15 0.52
BMT 0.81 1.42 0.33
Reticuloendothelial/immunity disorders 0.63 1.34 0.19
Infectious and parasitic diseases 0.89 1.69 0.08
OR procedures for infectious and parasitic diseases 1.05 1.52 0.30
Respiratory system diagnosis with ventilator support 1.11 1.36 0.42
Tracheostomy 0.79 1.35 0.19
COPD 0.68 1.11 0.09
Mean 0.80 1.43 0.30
DRG, diagnosis-related group; MedPAR, Medicare Provider Analysis and Review file; Asp, aspergillosis; BMT, bone marrow transplant; OR,
operating room; COPD, chronic obstructive pulmonary disease.
34 K.B. Tong et al.that are pulmonary in nature. The relatively low expendi-
tures found in these DRGs may reflect a significant percen-
tage of patients with localized or chronic disease within these
subgroups. According to the literature, mild-to-moderate
degrees of immunosuppression such as in the setting of
diabetes, advanced COPD, or low-dose corticosteroid ther-
apy, may place patients at risk for developing acute and
chronic forms of aspergillosis.
The DRGs for tracheostomy (483) and respiratory diag-
noses with ventilator support (475) represent gravely ill
patients, many of whom require substantial care in the
ICU. This is consistent with other studies in which cases of
aspergillosis in the ICU were reported.22
Increased hospital expenditures
These findings reinforce that aspergillosis has a critical
impact on expenditures and length of stay in high-risk
patient groups. Each of these variables was many times
higher in patients with aspergillosis than in patients
without infection. The impact of aspergillosis was
found to be particularly high in the setting of BMT. Addi-
tionally, these findings demonstrate that aspergillosis is a
devastating complication in the ICU population, associated
with very high costs. A separate sub-analysis of aspergil-
losis patients using artificial ventilation as a proxy for
intensive care confirmed these conclusions. These results
are consistent with the findings of previous studies:
Pelz and colleagues reported high attributable ICU costs
in critically ill patients with Candida infections,23 while a
study conducted by Vandewoude et al. found that stays
in ICU were associated with patients with invasive
aspergillosis.24
Furthermore, the high monetary costs of treating asper-
gillosis were reimbursed at a low level. For the DRGs that
were analyzed, hospital charges involving patients with
aspergillosis were reimbursed at an average rate of 7% lower
than hospitalizations without aspergillosis (35% vs. 42%,
respectively). In addition, aspergillosis-related incremental
hospital expenditures were generally reimbursed at well
below 30% of charges.Limitations
One concern about performing an analysis based on DRGs was
that high-risk patients could potentially be hidden within
non-specific DRG categories due to the rules of patient DRG
assignment. To explain this, the number of aspergillosis
patients within the top five most common DRGs, who had
a primary or secondary diagnosis of HIV, hematologic malig-
nancy, solid organ transplantation, BMT, chemotherapy, or
neutropenia based on an ICD-9-CM code, were identified and
counted. Relevant diagnoses were found in 23.5% of patients,
which suggests that while there is indeed some overlap, such
patients are in the minority.
Another limitation of the current study is the single ICD-9-
CM code for aspergillosis (117.3), which did not allow differ-
entiation between invasive aspergillosis and other more
chronic forms of Aspergillus infection. However, by utilizing
the secondary code of pneumonia in aspergillosis (484.6) to
stratify cases, aspergillosis patients with this secondary diag-
nosis were found to incur higher costs and have worse out-
comes than thosewho do not carry this diagnosis. This level of
analysis was not carried throughout the entire study due to
sample size constraints. Instead, most of these results are
based on a sample of the entire aspergillosis patient popula-
tion, including those with localized disease as well as acute
systemic infection. It is probable, however, that observations
for per-case mortality, LOS, and hospital charges and esti-
mated costs underestimated those of patients who have had
invasive, systemic disease.
Under-diagnosis of invasive aspergillosis has also been cited
as amajor issue in previous studies. This analysis is also subject
to these limitations as the study populations were identified
using the clinical diagnosis reported with hospital discharge
data, which is subject to the discretion of the treating phy-
sician and the diagnostic tools available to them. Current
estimates of the rate of under-diagnosis vary; however, one
studyof BMTpatients found that uponpostmortemevaluation,
45% had gone untreated for aspergillosis.25 These trends may
understate the total cost of care estimated in this analysis.
Future analyses ofmore recent datamay lend amore accurate
427.31 Atrial fibrillation 11.7%
284.80 Aplastic anemia
(not elsewhere specified)
11.1%
276.50 Volume depletion unspecified 9.6%
285.90 Anemia (not
otherwise specified)
9.1%
The economic impact of aspergillosis 35assessment of total costs, as newer molecular diagnostics will
probably increase diagnostic rates for aspergillosis. Our esti-
mates also do not account for the additional costs associated
with follow-up treatment in the hospital outpatient and home
health setting. However, previous studies have suggested that
hospital costs represent 90% of the total mean cost associated
with invasive aspergillosis.26
Concluding remarks
The present study demonstrates that aspergillosis has a
strong economic impact across many DRGs. The broad, het-
erogeneous nature of the population affected by aspergillosis
makes it challenging to direct healthcare resources effec-
tively, in order to address the problem that the disease
imposes on healthcare outcomes. In addition to determining
and improving guidelines for both prophylaxis and treatment
of fungal infections, it is necessary to expand consideration
to groups not considered to be typically at high risk.
Aspergillosis particularly affects drug, accommodation
(LOS), and ICU expenditures. While much of the attention
paid to aspergillosis has been directed towards patients who
are severely immunocompromised, more should be directed
towards other subgroups such as the chronically ill or ICU
patients in terms of both preventative and therapeutic inter-
ventions.
With reimbursement of aspergillosis-related cases at less
than a third of hospital expenditures, providers are placed in
the unenviable position of confronting a life-threatening and
costly disease with poor outcomes while facing difficult
economic constraints. We recommend a strong focus on
the development of more cost-effective approaches to the
disease, including new therapies as well as prophylactics,
which may reduce the onset of infection. The findings of this
study underscore the critical need for more research to
identify settings of care and specific risk factors that drive
increased expenditures.
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diagnoses reported with aspergillosis
ICD-9-CM Description Percent of
aspergillosis
discharges
484.60 Pneumonia in aspergillosis 37.2%
401.90 Hypertension
(not otherwise specified)
21.0%
518.81 Acute respiratory failure 16.5%
496.00 Chronic airway obstruction
(not elsewhere classified)
13.4%
428.00 Chronic heart failure
(not otherwise specified)
13.2%
491.21 Obstructive chronic
bronchitis with (acute)
exacerbation
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